PALB2

New Releases

Premium

Myriad Genetics' Panexia Predictive Pancreatic Cancer Test

The company is planning to develop a new diagnostic test for early detection of pancreatic cancer by combining PALB2 gene mutations with mutations in the BRCA 2 gene and p16 genes, to which Myriad also holds exclusive rights under 10 issued US patents. The test is slated for launch in 2010.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.